Duration of Urinary Catheterization Following Cesarean Deliveries Under Neuraxial Anesthesia
Launched by UNIVERSITY OF BRITISH COLUMBIA · Mar 11, 2025
Trial Information
Current as of May 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how long urinary catheters, which are used during cesarean deliveries, stay in place after the surgery. Catheters help empty the bladder when patients are recovering and may have trouble urinating due to pain medications. The study aims to see if keeping the catheters in for a shorter time, as recommended by medical guidelines, can help reduce issues like urinary tract infections and delays in recovery. Researchers will also look at anxiety levels in new mothers, as feeling anxious can affect how quickly they recover after a cesarean section.
To be part of this study, participants need to be women aged 19 and older who are having a cesarean delivery at BC Women's Hospital using a specific type of anesthesia (spinal or epidural). They should be able to speak and read English and will need to stay in the hospital for about 24 hours after the surgery. Those who agree to participate will contribute valuable information that could improve care for future mothers undergoing cesarean deliveries.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Patients ≥19 years of age.
- • Undergoing cesarean delivery (elective or emergent) at BC Women's Hospital.
- • Neuraxial anesthesia as their primary mode of anesthesia (spinal, epidural, combined spinal-epidural, dural-puncture epidural).
- • In-patient status at 24 (+/- 8) hours.
- • Self-reported proficiency in speaking and reading English.
- Exclusion Criteria:
- • Refusal to participate.
- • Inability to provide informed consent.
- • Other surgery (i.e. cervical cerclage) or delivery modes (i.e. operative vaginal delivery).
- • De novo general anesthetic, or patients who had a conversion from neuraxial to a general anesthetic.
- • Communication from patient's nurse indicating that it is not appropriate to approach due to distressing birth experience and/or outcome.
About University Of British Columbia
The University of British Columbia (UBC) is a leading research institution located in Vancouver, Canada, renowned for its commitment to advancing health sciences through innovative research and education. As a prominent clinical trial sponsor, UBC leverages its interdisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical studies aimed at improving patient outcomes across various medical fields. The university fosters collaborations with healthcare professionals, industry partners, and community stakeholders to translate research findings into practical applications, thereby contributing to the global advancement of medicine and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vancouver, British Columbia, Canada
Patients applied
Trial Officials
Anton Chau, MD MMSc
Principal Investigator
University of British Columbia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported